Skip to content
LATEST
Health

Bariatric surgery group loses 28.2% after GLP-1 use

Cleveland Clinic researchers compared five post-treatment paths in 20,486 adults, with discontinuation linked to 4% average loss over two years.

Bariatric surgery group loses 28.2% after GLP-1 use

Cleveland Clinic researchers found greater two-year weight loss after bariatric surgery or GLP-1 switching than after stopping treatment, in a study published Nov. 14 in eClinicalMedicine.

The observational analysis covered 20,486 adults with obesity or type 2 diabetes, making the findings useful for planning but not proof that one strategy was responsible for the weight differences.

GLP-1 medications, appetite-related drugs used in diabetes and weight management, included semaglutide and tirzepatide in the analysis. Participants had taken one of those medicines for at least 90 days before entering one of five post-treatment paths.

The groups were continuation of the original GLP-1, switching between semaglutide and tirzepatide, switching to another weight-loss medication, bariatric surgery, or discontinuation. Participants had an average age of 56.7 years, average weight of 109 kg and average body mass index of 38.

After two years, the bariatric surgery group lost an average of 28.2% of body weight, or about 31.5 kg. Those who switched between semaglutide and tirzepatide lost 16%, or about 18 kg, while those who stopped GLP-1 treatment lost 4%, or about 4.5 kg.

People who stayed on their original GLP-1 lost 10.9% of body weight, or 12.3 kg. Those who moved to another weight-loss medication lost 8.2%, or 9.2 kg.

Switching direction mattered in the reported results. Participants who changed from semaglutide to tirzepatide lost 3 kg more than those who continued semaglutide, while participants already using tirzepatide lost 4.5 kg more by continuing rather than changing to semaglutide.

Among participants with type 2 diabetes, HbA1c, a marker of average blood sugar over time, fell by 1.76% after bariatric surgery at one year. It fell 1.43% after GLP-1 switching, 1.32% after continuation and 0.48% after discontinuation.

Mir Ali, medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center, was not involved in the study. “We increasingly view medications and surgery as complementary tools rather than competing ones,” he said.

Ali said bariatric surgery remains an option for people with severe obesity, typically a body mass index of 35 or higher, or 30 or higher with metabolic conditions such as type 2 diabetes. He also said GLP-1 use before surgery can reduce liver volume and lower surgical risk.

The study cannot show that surgery or switching alone accounted for the larger losses, because participants were not described as randomly assigned to each path. It also applies to adults with obesity or type 2 diabetes who had already used semaglutide or tirzepatide for at least 90 days, not to all GLP-1 users.

Ali said people often stop GLP-1 treatment because of gastrointestinal side effects, supply issues or loss of insurance coverage. “Have a concrete ‘off-ramp’ plan in place with your doctor before taking your last dose, so you have medical, nutritional, or surgical support ready to protect the health gains you worked hard to achieve,” he said.

Source: Healthline News article, Nov. 19, 2026; eClinicalMedicine study, Nov. 14, 2026.

Atlas360 reports health research and does not provide medical advice.

More stories

Latest news